Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study
Part of paid clinical trials in Culver City, California.
- Sponsor
- Imugene Limited
- Study ID
- NCT05822427
- Status
- Recruiting
Conditions
- Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The goal of this observational study is to collect information on the long-term safety of study participants who received an Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Product in an Imugene Clinical Study. The main questions it aims to answer are: * What are the frequency, severity, duration, and outcome of clinically significant Clinical Events of Interest (CEI)? * What is the duration of response and overall survival time after taking an allogeneic CAR T-Cell product on an Imugene clinical study? Participants will have a yearly visit either face to face or remotely for up to 15 years to check for CEI.
Key Dates
- Start date
- Aug 25, 2020
- Status verified
- May 2025
- Primary completion
- Dec 31, 2039
- Completion
- Dec 31, 2039
Study Design
- Enrollment
- 75 participants (estimated)
Primary Outcome Measure
Frequency of Clinically Significant Clinical Events of Interest (CEI) [ Time Frame: Up to 15 years ]
Central Contacts
- Clinical Imugene Limited1 984 245 0082
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Science 37, Inc. | Culver City | California | 90230 | - |